Cite
Peuker CA, Yaghobramzi S, Grunert C, et al. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2021;162:45-55doi: 10.1016/j.ejca.2021.11.025.
Peuker, C. A., Yaghobramzi, S., Grunert, C., Keilholz, L., Gjerga, E., Hennig, S., Schaper, S., Na, I. K., Keller, U., Brucker, S., Decker, T., Fasching, P., Fehm, T., Janni, W., Kümmel, S., Schneeweiss, A., Schuler, M., Lüftner, D., & Busse, A. (2021). Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. European journal of cancer (Oxford, England : 1990), 16245-55. https://doi.org/10.1016/j.ejca.2021.11.025
Peuker, Caroline A, et al. "Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial." European journal of cancer (Oxford, England : 1990) vol. 162 (2021): 45-55. doi: https://doi.org/10.1016/j.ejca.2021.11.025
Peuker CA, Yaghobramzi S, Grunert C, Keilholz L, Gjerga E, Hennig S, Schaper S, Na IK, Keller U, Brucker S, Decker T, Fasching P, Fehm T, Janni W, Kümmel S, Schneeweiss A, Schuler M, Lüftner D, Busse A. Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2021 Dec 22;162:45-55. doi: 10.1016/j.ejca.2021.11.025. Epub 2021 Dec 22. PMID: 34953442.
Copy
Download .nbib